Abiomed recalls some Impella 5.5 with SmartAssist devices

2023-06-05
Abiomed — bought by Johnson & Johnson for $16.6 billion last year — recalled 466 affected devices. It distributed these Impella 5.5 with SmartAssist devices between Sept. 28, 2021, and March 6, 2023. The company initiated its recall on April 17. 2023. Impella 5.5 with SmartAssist supports the pumping chambers of the heart for up to 14 days when cardiogenic shock occurs less than 48 hours after a severe heart attack, open-heart surgery or when the heart functions poorly due to cardiomyopathy. Abiomed received customer complaints around the device relating to purge fluid leaking from the purge sidearm of the pump. Purge leak occurrence leads to low purge pressures in the device, prompting alarms and requiring evaluation. If left unresolved, this issue could lead to pump stoppage and loss of therapy. Patients in critical condition could experience further deterioration and worsened conditions if the pump fails. It could lead to serious injury or death. To date, Abiomed received 179 complaints related to the recall. It reports three injuries and no deaths as a result, according to the FDA notice. Abiomed’s urgent medical device recall letter recommended users examine their inventory immediately. Customers should not use affected products unless they have no other available product.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。